中华流行病学杂志
中華流行病學雜誌
중화류행병학잡지
CHINESE JOURNAL OF EPIDEMIOLOGY
2013年
7期
728-731
,共4页
万利平%贺润莲%艾永梅%张慧敏%邢敏%杨林%宋艳龙%余红梅
萬利平%賀潤蓮%艾永梅%張慧敏%邢敏%楊林%宋豔龍%餘紅梅
만리평%하윤련%애영매%장혜민%형민%양림%송염룡%여홍매
阿尔茨海默病%项目功能分析%项目反应理论%生命质量
阿爾茨海默病%項目功能分析%項目反應理論%生命質量
아이자해묵병%항목공능분석%항목반응이론%생명질량
Alzheimer's disease%Item function analysis%Item response theory%Quality of life
目的 对中文版阿尔茨海默病(AD)生命质量量表(QOL-AD)进行项目功能分析,以确定QOL-AD是否适用于中国大陆AD患者.方法 采用分层整群抽样抽取200例AD患者;生命质量测量采用中文版QOL-AD;利用Multilog 7.03软件进行项目功能分析,得出QOL-AD各条目的区分度a,难度系数b,并确定项目特征曲线(ICC).结果 除了第1条和第7条项目的区分度<0.6外,其余均>0.6;除了第1条和第7条项目的ICC形态不甚理想,其他均为第一条和第四条曲线呈单调,而中间两条则呈先升后降的趋势,并且坡度较陡.结论 QOL-AD的项目功能良好,基本适用中国大陆AD患者.
目的 對中文版阿爾茨海默病(AD)生命質量量錶(QOL-AD)進行項目功能分析,以確定QOL-AD是否適用于中國大陸AD患者.方法 採用分層整群抽樣抽取200例AD患者;生命質量測量採用中文版QOL-AD;利用Multilog 7.03軟件進行項目功能分析,得齣QOL-AD各條目的區分度a,難度繫數b,併確定項目特徵麯線(ICC).結果 除瞭第1條和第7條項目的區分度<0.6外,其餘均>0.6;除瞭第1條和第7條項目的ICC形態不甚理想,其他均為第一條和第四條麯線呈單調,而中間兩條則呈先升後降的趨勢,併且坡度較陡.結論 QOL-AD的項目功能良好,基本適用中國大陸AD患者.
목적 대중문판아이자해묵병(AD)생명질량량표(QOL-AD)진행항목공능분석,이학정QOL-AD시부괄용우중국대륙AD환자.방법 채용분층정군추양추취200례AD환자;생명질량측량채용중문판QOL-AD;이용Multilog 7.03연건진행항목공능분석,득출QOL-AD각조목적구분도a,난도계수b,병학정항목특정곡선(ICC).결과 제료제1조화제7조항목적구분도<0.6외,기여균>0.6;제료제1조화제7조항목적ICC형태불심이상,기타균위제일조화제사조곡선정단조,이중간량조칙정선승후강적추세,병차파도교두.결론 QOL-AD적항목공능량호,기본괄용중국대륙AD환자.
Objective To introduce the Item Function Analysis (IFA) of Quality of Life-Alzheimer' s disease (QOL-AD) Chinese version and to explore the feasibility of its application on Chinese patients with AD.Methods Two hundred AD patients were interviewed and assessed by QOL-AD,through the stratified cluster sampling method.Multilog 7.03.was used for Item Function Analysis.Difference scale (a),difficulty scale (b) and Item Characteristic Curve (ICC) of each item of QOL-AD were provided.Results Different scales of the item 1,7 were below 0.6,while all the others were above 0.6.As for ICC.The first and last lines for the other items were monotonic in which the two in between were in inverted V-shape,with very steep slopes,except for the item 1 and 7.Conclusion Results form the IFA showed that QOL-AD was applicable to be used in the Chinese patients with AD.